Boardroom Alpha
Boardroom Alpha
FRPT · Current Report (Form 8-K) · Filed February 4, 2026

Freshpet Inc — Current Report (Form 8-K)

Form
8-K
Filed
February 4, 2026
Period
Feb 4, 2026
Ticker
FRPT
Accession
0000929638-26-000488
Boardroom Alpha · Filing insights

Freshpet appoints John O’Connor as CFO effective Feb 9, 2026; grants 7,500 RSUs and a comprehensive compensation package.

About Freshpet Inc
Market cap
$2.5B
1Y TSR
−30.3%
3Y TSR
−6.3%
Board grade
C+
Sector
Consumer Defensive
CEO
William B Cyr
Last annual meeting: Jun 10, 2026 · View full Freshpet Inc profile →


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  February 4, 2026

Freshpet, Inc.
(Exact name of registrant as specified in its charter)

Delaware
 
001-36729
 
20-1884894
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

1450 US-206
Bedminster, New Jersey
 
07921
(Address of principal executive offices)
 
(Zip code)

Registrant's telephone number, including area code:  201 520-4000


(Former Name or Former Address, if Changed Since Last Report)
___________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
FRPT
The NASDAQ Global Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Chief Financial Officer
On February 4, 2026, Freshpet, Inc. (the “Company”) announced the appointment of Mr. John O’Connor to serve as Chief Financial Officer of the Company, effective as of February 9, 2026 (the “Effective Date”).  Mr. O’Connor, age 45, joins the Company after having previously served as Senior Vice President, Global Commercial Finance of Zoetis Inc. (“Zoetis”), a global animal health company listed on the New York Stock Exchange, in 2025, and as Senior Vice President, US Commercial Finance Lead of Zoetis from 2023 to 2025. He also served as Chief Financial Officer of Thrive Pet Healthcare from 2021 to 2023.  Prior to that he held various roles at Zoetis from 2012 to 2021, including as Senior Vice President and Head, Finance, U.S. Operations from 2020 to 2021 and Senior Vice President, Finance, Investor Relations and Treasury from 2016 to 2020.
Mr. O’Connor will receive an annual base salary of $525,000 (“Base Salary”).  He will also be eligible to participate in the Company’s annual cash bonus program, with an annual target bonus opportunity of at least seventy percent (70%) of his Base Salary, as well as the Company’s long-term equity incentive program, with a target opportunity of at least one hundred fifty percent (150%) of his Base Salary, based in each case on parameters established by the Company’s board of directors (the “Board”), or a committee thereof.  Mr. O’Connor is also eligible to participate in the Company’s executive severance plan and other benefit programs available to Company employees, and shall be entitled to five (5) weeks of vacation to be taken in accordance with Company policy.
As an inducement to Mr. O’Connor to join the Company, the Compensation and Human Capital Management Committee of the Board has determined to grant Mr. O’Connor restricted stock units in respect of seventy-five hundred (7,500) shares of the Company’s common stock on and as of the Effective Date (the “Restricted Stock Units”), which will vest in equal installments on each of the first three anniversaries of Effective Date, subject to Mr. O’Connor’s continued employment through such dates.

There are no arrangements or understandings between Mr. O’Connor and any other persons outside of the Company pursuant to which he was selected as an executive officer of the Company, and there are no family relationships between any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company and Mr. O’Connor. Mr. O’Connor has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Reassignment of Interim Chief Financial Officer
Upon the commencement of Mr. O’Connor’s employment as Chief Financial Officer on the Effective Date, Mr. Ivan Garcia will step down from his position as Interim Chief Financial Officer but will continue to serve the Company as Senior Vice President, Finance. The Company appreciates Mr. Garcia’s diligent service as Interim Chief Financial Officer and looks forward to his continued support.

 
Item 7.01 Regulation FD Disclosure.
On February 4, 2026, the Company issued a press release announcing the appointment of Mr. O’Connor. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.


Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
 
104
Cover Page Interactive Data File (formatted as inline XBRL)


SIGNATURE
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: February 4, 2026

 
FRESHPET, INC.
     
 
By:
/s/ Lisa Alexander
 
Name:
Lisa Alexander
 
Title:
General Counsel and Corporate Secretary
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Freshpet Inc (FRPT)

Reference

Frequently asked questions

When did Freshpet Inc file this 8-K?
Freshpet Inc (FRPT) filed this Current Report (Form 8-K) with the SEC on February 4, 2026. The accession number assigned by EDGAR is 0000929638-26-000488.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Freshpet appoints John O’Connor as CFO effective Feb 9, 2026; grants 7,500 RSUs and a comprehensive compensation package. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Freshpet Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Freshpet Inc has filed under CIK 1611647, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer